OsteoStrong is not an outright hoax, but its central promise, that once-weekly 10-minute sessions can meaningfully increase bone density, is not supported by strong clinical evidence. The most rigorous study to date, a 2025 pilot study of 44 postmenopausal women, found no significant improvement in bone density at the hip or spine after eight months of use. A scoping review published the same year concluded that effects on bone strength “are inconsistent” across all existing trials, and no randomized controlled trial has ever compared OsteoStrong to a simple control group.
What OsteoStrong Actually Is
OsteoStrong is a franchise business with hundreds of locations, primarily in the United States. Members visit once a week for a session lasting about 10 to 15 minutes. During that session, they use four machines that target different parts of the body: a chest press, a leg press, a core pull, and a vertical lift designed to load the spine. The company calls these “growth triggers.”
The idea behind the machines is osteogenic loading, a real biological principle. When bones experience force well beyond what they encounter in daily life, they respond by becoming denser. OsteoStrong’s marketing cites research suggesting that bone remodeling requires forces of roughly 4.2 times a person’s body weight. The machines are designed to let users push or pull against resistance at very specific joint angles where they can generate the most force, similar to an isometric exercise held at the strongest point in a movement.
The concept of mechanical loading for bone health is legitimate and well established in exercise science. The question is whether this particular system delivers enough of that stimulus to produce real-world bone density changes, and whether the evidence backs up the company’s marketing.
What the Clinical Evidence Shows
The strongest piece of evidence available is a 2025 pilot study published in a peer-reviewed journal. Researchers enrolled 44 postmenopausal women who had low bone mineral density (but not severe osteoporosis) and tracked them through eight months of supervised, once-weekly OsteoStrong sessions. Adherence was good, meaning participants actually showed up consistently. Despite that, the results were discouraging.
Bone density at the total hip, femoral neck, and lumbar spine did not change. At the wrist and shin, where researchers used high-resolution imaging to look at bone microarchitecture, density actually decreased slightly. Cortical thickness at the wrist dropped, and the spacing between tiny bone structures in the shin increased, both signs of mild deterioration rather than improvement. The authors concluded that OsteoStrong “does not significantly improve bone density, microarchitecture, or strength in healthy postmenopausal women with low BMD.”
Beyond that single pilot study, a scoping review surveying all available OsteoStrong research found that effects on bone mineral density were “inconsistent across trials.” Most existing studies had small sample sizes, some as few as nine participants, and many had potential conflicts of interest. None were adequately powered randomized controlled trials, the gold standard for determining whether a treatment works. None compared OsteoStrong to a generic high-intensity resistance exercise program, so even where small positive trends appeared, there’s no way to know if the branded system offers anything beyond what regular weight training provides.
The 4.2x Body Weight Claim
OsteoStrong frequently references the idea that bones need loading equal to 4.2 times body weight to trigger new growth. This figure comes from a cross-sectional study conducted in the United Kingdom that used accelerometers on teenagers. The Bone Health and Osteoporosis Foundation has acknowledged this research but cautions that “we must be careful in generalizing the results to other populations.” A threshold observed in active adolescents, whose bones are still growing rapidly, may not apply to a 65-year-old woman with thinning bones. Using this single number as a cornerstone of marketing aimed at postmenopausal women is a significant stretch of the original science.
How It Compares to Regular Exercise
High-intensity resistance training has decades of research showing it can slow bone loss and, in some cases, modestly increase bone density at key fracture sites like the hip and spine. Programs using heavy squats, deadlifts, and presses two to three times per week have produced measurable improvements in controlled trials with postmenopausal women. These programs typically cost far less than an OsteoStrong membership.
No study has directly compared OsteoStrong to standard resistance training. That’s a critical gap because, without that comparison, you can’t determine whether the branded machines offer any advantage. The scoping review specifically noted this absence. If you’re already doing heavy strength training, the marginal benefit of adding OsteoStrong is completely unknown. If you’re choosing between the two, the evidence base for traditional resistance exercise is substantially stronger.
Regulatory Status
OsteoStrong’s equipment received a De Novo classification from the FDA in January 2024. This means the FDA recognized it as a new type of device and created a regulatory category for it. However, FDA clearance of a device is not the same as FDA approval of a medical treatment. The classification does not mean the FDA has validated OsteoStrong’s marketing claims about bone density improvement or endorsed it as a treatment for osteoporosis. The distinction matters because franchise locations sometimes reference the FDA classification in ways that could imply clinical endorsement.
What Users and Experts Have Reported
Discussion threads on Mayo Clinic Connect and similar forums reveal a consistent pattern. Some users report feeling stronger, having better balance, or experiencing less back pain after regular sessions. These subjective benefits are real and worth acknowledging. Feeling more confident in your body and more stable on your feet has genuine value, particularly for older adults at risk of falls.
However, exercise physiologists and bone researchers who have reviewed OsteoStrong’s cited studies have raised pointed concerns. As one analysis shared on Mayo Clinic Connect noted, the company’s own referenced manuscripts describe “small uncontrolled studies” and “none of the studies were adequately powered randomized controlled trials investigating the effects of the OsteoStrong exercise program on BMD outcome.” The conclusion from that review: “the evidence presented does not demonstrate efficacy of the OsteoStrong program on BMD outcomes.”
The Bottom Line on Value
OsteoStrong memberships typically run several hundred dollars per month. For that price, you get four machine-based movements once a week for about 10 minutes. The sessions are supervised and simple, which appeals to people who dislike gyms or feel intimidated by free weights. That convenience has real value for certain people.
What you’re not getting, based on current evidence, is a proven method for increasing bone density. The best available study showed no improvement after eight months, and the broader body of research is too small, too inconsistent, and too riddled with conflicts of interest to draw confident conclusions. Calling OsteoStrong a “hoax” implies deliberate fraud, which is hard to prove. But the gap between what the marketing promises and what the science currently supports is wide. If your primary goal is protecting your bones, the strongest evidence still points toward traditional high-intensity resistance training, adequate calcium and vitamin D intake, and, when appropriate, medication prescribed by your physician.